Match Document Document Title
8999297 Hemostatic agent  
A generally non-acidic hemostatic agent, having a relatively neutral pH comprising a magnesium compound, such as a magnesium chloride, a magnesium sulfate and/or a magnesium acetate based...
8999333 Human tissue factor antibody and uses thereof  
The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to...
8987190 Treatment of acute ischemic stroke or intracranial bleeding with tPa and carbamylated erythropoietin  
The present invention relates a method for the treatment of intracranial bleeding comprising administration of a therapeutically effective amount of tPa and a therapeutically effective amount of...
8969299 Therapeutic agents for regulating serum phosphorus  
Methods for modulating serum phosphorus levels are described, wherein calcimimetic agents are administered to a subject in need thereof. In one embodiment, the compound is cinacalcet, and in other...
8962562 Use of histones for therapeutic purposes  
The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of...
8946160 Nitric oxide amino acid esters for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation  
Use of nitric oxide amino acid esters for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation, such as peripheral vascular...
8946161 Method of treatment using stable liquid formulation of G-CSF  
Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such...
8945895 Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof  
Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching...
8921367 Use of AMG 900 for the treatment of cancer  
The present invention relates to methods of using AMG 900, a small molecule pan aurora kinase inhibitor, for the treatment of cancer, including solid tumors, hematologically derived tumors and the...
8911789 Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom  
Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be...
8906855 Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries  
A pharmaceutical composition comprising an amphiphilic emulsifier, a polar liquid carrier and, optionally, a lipid component. The amphiphilic emulsifier form free-moving, optionally...
8895016 Antagonists of activin-actriia and uses for increasing red blood cell levels  
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly...
8889374 Recombinant codon optimised factor H  
The present invention relates to recombinant factor H and variants and conjugates thereof and methods of their production, as well as uses and methods of treatment involving the materials.
8883153 Methods for preventing and treating angioedema  
One aspect of the present invention provides a method of treating or preventing angioedema in a patient in need thereof comprising administering to the patient a therapeutically effective amount...
8877710 Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof  
The present invention relates to compounds for treatment that protects the endothelium, prevent pathologic thrombus formation in the microcirculation and preserve platelet number and function and...
8865649 Preparation for use of aspartate and vitamin B12 or biotin for regulating ketone bodies  
It has been found that high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, especially in relative absence of glutamate equivalents, improve the metabolism of...
8865154 Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface  
The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include...
8853161 Glycopegylation methods and proteins/peptides produced by the methods  
The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a...
8846619 Artificial oxygen transport protein  
This invention provides heme-containing peptides capable of binding molecular oxygen at room temperature. These compounds may be useful in the absorption of molecular oxygen from molecular...
8840897 Preparation useful for, and method for treatment of neonatal alloimmune thrombocytopenia (NAIT)  
A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal...
8815250 Clotting factor-Fc chimeric proteins to treat hemophilia  
The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a...
8808748 Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same  
Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding...
8802620 Demannosylated recombinant factor VIII for the treatment of patients with haemophilia A  
There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor...
8791070 Glycopegylated factor IX  
Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the...
8753670 Fibrin foam and process  
A fibrin wound dressing is made by mixing quantities of fibrinogen solution and thrombin solution with air. The resulting foam is very light weight, and with the proper attention to the amount of...
8741844 Use of mutated antithrombins for treating or preventing coagulation disorders  
Use of a mutated antithrombin having substantially no activity, in particular no anticoagulant activity, possibly in association with an anticoagulant, for the preparation of a drug intended for...
8735352 Adsorbent for blood coagulation factor or cell adhesion factor and method for purifying the factor  
An objective of the invention is to provide an adsorbent allowing purification of a blood coagulation factor or a cell adhesion factor under mild conditions, according to simple procedures, and at...
8716225 Kallikrein inhibitors and anti-thrombolytic agents and uses thereof  
Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or...
8715672 Treatment of diseases linked to pathological kinin formation  
The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and for preventing the formation and/or the stabilization of three dimensional...
8715654 Methods of modulating the negative chemotaxis of immune cells  
The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.
8703706 Closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit  
The present invention relates to a closed container holding a composition of an activated Factor VII polypeptide in an amount of in the range of 2.5-90 mg per imL volume of the container. The...
8703695 Biologically active peptides and their new uses  
Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual.
8697645 Second generation low oxygen affinity pegylated hemoglobins as oxygen-carrying plasma expanders  
Provided are hemoglobins having at least two chemical modifications that lower oxygen affinity, hemoglobins chemically modified by the addition of glyceraldehyde-3-phosphate, and hemoglobins...
8679482 Method of promoting healing of a tympanic membrane perforation using plasminogen  
The present invention relates to the use of plasminogen and plasmin as agents for enhancing healing of tympanic membrane perforations or other wounds, and for reducing scars or necrotic tissue...
8680069 Modified polynucleotides for the production of G-CSF  
The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed...
8658592 Biologically active peptides and their new uses  
Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual.
8653030 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release  
A formulation containing a biologically active compound having a chemical structure with hydrogen bonding sites, a first biocompatible, hydrolytically degrading polycarbonate with hydrogen bonding...
8637448 Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface  
The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include...
8632771 High molecular weight derivatives of vitamin K-dependent polypeptides  
Modifications of vitamin K-dependent polypeptides that lead to enhanced protein function on a weight or molar basis and/or increase of protein lifetime in the circulation are described. Both...
8623823 Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist  
Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a...
8623810 Protease for wound conditioning and skin care  
We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds....
8618056 Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries  
A pharmaceutical composition comprising a lipid component; an amphiphilic emulsifier; and a polar liquid carrier. The lipid component and the amphiphilic emulsifier form free-moving lipid-carrying...
8618063 Method for treating a synucleinopathy  
The present invention relates to methods for restoring fast axonal transport in a cell which expresses a pathological synuclein protein and for treating a synucleinopathy using a Protein Kinase C...
8609130 Method for activating hemostatic systems by applying a hemostatic textile  
The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of...
8609693 Methods of administration of thrombopoietin agonist compounds  
The embodiments provide methods of administering a high dose or a loading dose of a TPO modulator to a subject. The embodiments further provide methods of treating thrombocytopenia and/or...
8586048 G-CSF immunoglobulin fusion proteins  
Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc...
8586525 Biologically active peptides and their new uses  
Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual.
8586528 Biologically active peptides and their new uses  
Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual.
8580737 Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates  
The field of the invention is the treatment of acquired bleeding, a clinical condition associated with severe traumatic, peri- or post-operative bleeding. A novel treatment is proposed in which...
8569236 Resuscitation fluid  
A method for treating conditions related to lack of blood supply with a lipid based resuscitation fluid is disclosed. The resuscitation fluid contains a lipid component and an aqueous carrier. The...